



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

Meeting to commence at 9.30 am on Tuesday 9th November 2021

via Zoom

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of the previous meeting** 1/AWMSG/1121
5. **Chairman's report**
6. **Cellulitis Pathway for People with Lymphoedema or Chronic Oedema in NHS Wales** (for acknowledgement) 2/AWMSG/1121
7. **All Wales Adult Asthma Management and Prescribing Guidelines (2021 update)** (for endorsement) 3/AWMSG/1121
8. **All Wales COPD Management and Prescribing Guidelines (2021 update)** (for endorsement) 4/AWMSG/1121
9. **National Prescribing Indicators 2022 – 23** (for endorsement) 5/AWMSG/1121
10. **Appraisal 1: Paediatric Licence Extension** 6/AWMSG/1121
Ustekinumab (Stelara®) for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 to 11 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies appendices
11. **Appraisal 2: Paediatric Licence Extension** 7/AWMSG/1121
Glecaprevir/pibrentasvir (Maviret®) for the treatment of chronic hepatitis C virus (HCV) infection in children aged 3 years to <12 years appendices

Any other business

Date and time of next meeting: Wednesday 8th December 2021

